FDA Approves the First 3D Printed Drug Product

Aprecia Introduces its First Product Using the ZipDose® Formulation Platform for the Treatment of Epilepsy   BLUE ASH, Ohio, August 3, 2015 – Aprecia Pharmaceuticals Company today announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM® levetiracetam for oral use as a Read More »

Image courtesy of Aprecia Pharmaceuticals Company